WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoPreface
Ver el documentoIntroduction
Abrir esta carpeta y ver su contenidoParasitic infections
Abrir esta carpeta y ver su contenidoInsect and arachnid bites and stings
Abrir esta carpeta y ver su contenidoSuperficial fungal infections
Abrir esta carpeta y ver su contenidoSubcutaneous fungal infections
Abrir esta carpeta y ver su contenidoBacterial infections
Abrir esta carpeta y ver su contenidoViral infections
Abrir esta carpeta y ver su contenidoEczematous diseases
Abrir esta carpeta y ver su contenidoScaling diseases
Abrir esta carpeta y ver su contenidoPapulosquamous diseases
Ver el documentoCutaneous reactions to drugs
Abrir esta carpeta y ver su contenidoPigmentary disorders
Abrir esta carpeta y ver su contenidoPremalignant lesions and malignant tumours
Abrir esta carpeta y ver su contenidoPhotodermatoses
Abrir esta carpeta y ver su contenidoBullous dermatoses
Ver el documentoAlopecia areata
Ver el documentoUrticaria
Abrir esta carpeta y ver su contenidoConditions common in children
Ver el documentoAcne vulgaris
Ver el documentoPruritus
Ver el documentoTropical ulcers
Abrir esta carpeta y ver su contenidoAntimicrobial drugs
Abrir esta carpeta y ver su contenidoAntifugal drugs
Abrir esta carpeta y ver su contenidoAntiseptic agents
Abrir esta carpeta y ver su contenidoKeratoplastic and keratolytic agents
Abrir esta carpeta y ver su contenidoScabicides and pediculicides
Abrir esta carpeta y ver su contenidoAnti-inflammatory and antipruritic drugs1
Cerrar esta carpetaAntiallergics and drugs used in anaphylaxis
Ver el documentoChlorphenamine
Ver el documentoAlternative antihistamines
Ver el documentoEpinephrine
Abrir esta carpeta y ver su contenidoUltraviolet radiation-blocking agents (sunscreens)
Abrir esta carpeta y ver su contenidoMiscellaneous drugs
Abrir esta carpeta y ver su contenidoAnnex
Ver el documentoSelected WHO Publications of Related Interest
Ver el documentoBack cover
 

Chlorphenamine

Tablet, 4 mg (hydrogen maleate)

General information

Chlorphenamine is an antihistamine that reversibly and competitively inhibits the binding of histamine to H1 receptors.

It is well absorbed following oral administration and is widely distributed throughout the body including the central nervous system. Plasma concentrations peak after 2-3 hours. It is metabolized in the liver and excreted in the urine, largely as metabolites.

Clinical information

Uses

Symptomatic treatment of:

• urticaria
• severe and intractable pruritus.

Dosage and administration

The dosage should be adjusted according to the patient’s response and tolerance.

Adults and children over 12 years: 4 mg every 6 hours.

Children under 12 years: 0.35 mg/kg daily in three or four divided doses.

Contraindications

Age under 2 years.

Precautions

Drowsiness, dizziness, blurred vision and psychomotor impairment can occur. These effects can seriously impair the patient’s ability to drive and use machinery.

Use in pregnancy

Safe use in pregnancy has not been established. Chlorphenamine should be used only when the need of the mother outweighs any possible risk to the fetus.

Adverse effects

Sedation, which can vary in degree from mild drowsiness to deep sleep is common, but patients rapidly develop tolerance. This effect may be of benefit in patients with pruritus. Other adverse effects on the central nervous system include dizziness, lassitude, incoordination and blurred vision. These effects are rarely observed with the newer H1 antagonists, which do not cross the blood-brain barrier.

Paradoxical excitation in children and confusional states in the elderly have been reported.

Gastrointestinal symptoms including anorexia, nausea, vomiting, epigastric pain and constipation or diarrhoea also occur.

Drug interactions

Alcohol and other drugs acting on the brain have an additive sedative effect. Phenytoin toxicity has resulted from inhibition of its metabolism.

Overdosage

Drowsiness, dizziness and ataxia are the most common symptoms of acute overdosage. Anticholinergic effects including flushing, dilated pupils and hyperthermia occur within 2 hours of ingestion. In serious cases, seizures are followed by respiratory and cardiovascular depression.

Induction of emesis or gastric lavage followed by administration of activated charcoal is of value when undertaken within a few hours of ingestion. Treatment is otherwise symptomatic and aims to maintain respiration and control seizures and cardiovascular abnormalities.

Storage

Tablets should be stored in well-closed containers, protected from light.

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019